IP Verse

Metabolically Optimized Cell Culture

PatentPatent Analysis

EP3351620

REGENERON PHARMACEUTICALS
Application Number
EP18161278A
Filing Date
Oct 10, 2014
Status
Revoked
Apr 22, 2022
Grant Date
Sep 2, 2020
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP4252857B1
EP3506931B1
EP3889181B1

Bibliography

The patent EP3351620B1 was granted to Regeneron Pharmaceuticals on Sep 2, 2020 following the initial filing on Oct 10, 2014 under the application number EP18161278A . The current legal status of the patent is Revoked.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions filed by Competitors

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

BREUERJun 2, 2021ADMISSIBLE
NEUEFEINDJun 2, 2021ADMISSIBLE

Dossier Documents of the Patent

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents